共 50 条
Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: Evidence and controversies
被引:31
|作者:
Johri, A. M.
[1
]
Heyland, D. K.
[2
,3
]
Hetu, M. -F.
[1
]
Crawford, B.
[1
]
Spence, J. D.
[4
,5
]
机构:
[1] Queens Univ, Dept Med, Div Cardiol, Cardiovasc Imaging Network, Kingston, ON K7L 2V7, Canada
[2] Queens Univ, Dept Med, Div Community Hlth & Epidemiol, Kingston, ON K7L 2V7, Canada
[3] Queens Univ, Clin Evaluat Res Unit, Kingston, ON K7L 2V7, Canada
[4] Robarts Res Inst, London, ON N6A 5C1, Canada
[5] Univ Western Ontario, London, ON, Canada
关键词:
Metabolic syndrome;
Diabetes;
Atherosclerosis;
Cardiovascular disease;
Coronary artery disease;
Plaque;
L-Carnitine;
PROPIONYL-L-CARNITINE;
LOW-DENSITY-LIPOPROTEIN;
ACETYL-L-CARNITINE;
PLASMA ADIPONECTIN LEVELS;
FATTY-ACID OXIDATION;
MYOCARDIAL-INFARCTION;
INSULIN-RESISTANCE;
ATHEROSCLEROTIC LESIONS;
MICROBIOTA METABOLISM;
GLUCOSE-OXIDATION;
D O I:
10.1016/j.numecd.2014.03.007
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
As the incidence of metabolic syndrome increases, there is also a growing interest in finding safe and inexpensive treatments to help lower associated risk factors. L-carntine, a natural dietary supplement with the potential to ameliorate atherosclerosis, has been the subject of recent investigation and controversy. A majority of studies have shown benefit of L-C supplementation in the metabolic syndrome or cardiovascular risk factors. However, recent work has suggested that dietary L-C may accelerate atherosclerosis via gut microbiota metabolites, complicating the role of L-C supplementation in health. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:808 / 814
页数:7
相关论文